colorectal cancer: what’s new and what’s on the horizon
DESCRIPTION
Every summer, the American Society for Clinical Oncology (ASCO) brings together internationally renowned cancer researchers, doctors and medical professionals to discover and discuss the latest in cancer research and patient care. This webinar, scheduled for June 19 2013 is presented by Dr. John Marshall, and will highlight the key colorectal cancer findings from the 2013 meeting and what these advances mean for you.TRANSCRIPT
![Page 1: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/1.jpg)
Save the date for our 10th National Patient Conference
Learn more or register:www.ccalliance.org or 1-877-422-2030
![Page 2: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/2.jpg)
Presented by:
![Page 3: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/3.jpg)
Fight Colorectal CancerMissionFight Colorectal Cancer demands a cure for colon and rectal cancer. We educate and support patients, push for changes in policy that will increase and improve research, and empower survivors to raise their voices against the status quo.
Monthly Patient Webinar Series3rd Wednesday every monthFightColorectalCancer.org Fight CRC Toll-free Answer Line 1.877.427.2111
Join One Million StrongCRCMillionStrong.org
Join us in March 2014 for Call on Congress
![Page 4: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/4.jpg)
Fighting a Smarter War On Colon Cancer:
John L. Marshall, MD
The Biomarker Divide
Tel: (202) 444-0275Fax: (202) 444-1229
http://lombardi.georgetown.edu/GI
![Page 5: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/5.jpg)
Stakeholder Motivation
Stakeholders• FDA• CMS/Payers• NCI/CTEP• PhRMA• Community Onc• Academic Onc• Patients
Priority/Agenda• Safety and Efficacy• Cost Control/Value• Cure Cancer• Markets, ROI• Efficient/Quality Care• Clinical Trial Accrual• Cure/Benefit/Altruism
![Page 6: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/6.jpg)
Gastrointestinal (GI) Cancers Facts
GI cancers represent the most common and fatal cancers in the world
2009: 275,720 new diagnosis of GI Cancers and 135,830 deaths in the US alone
Anal Cancer Colorectal Cancer Esophageal Cancer Gallbladder Cancer Liver Cancer Pancreatic Cancer Small Intestine Cancer Stomach/Gastric Cancer
No two cancers are alike and treatments must be selected based on an individual’s tumor characteristics, by personalized medicine
![Page 7: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/7.jpg)
Breast Cancer Nation
![Page 8: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/8.jpg)
Why Not Brown?
![Page 9: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/9.jpg)
Our Current Model of Colon Cancer
![Page 10: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/10.jpg)
Antoni van Leeuwenhoek (1632-1723)
Invented the microscope around
166810
![Page 11: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/11.jpg)
The view from 35,000 feet
Everything looks the same from up here
![Page 12: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/12.jpg)
12
Management of MCRC: An Evolving Treatment Algorithm
Diagnosis of MCRC
Resectable Unresectable
Adjuvant therapy
Surgery
Neo-adjuvant/Pre-operative
therapy
First-Line
Second-Line
Third-Line
Borderline/PotentiallyResectable
Fourth-Line
Treatment continuum
![Page 13: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/13.jpg)
13
Advances in the Treatment of Colorectal Cancer
2000 2005 2008 2012
Capecitabine
Oxaliplatin
Cetuximab
Irinotecan
5-FU
Panitumumab
Targeted therapies
Bevacizumab
KRASAfliberceptRegorafanib
![Page 14: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/14.jpg)
2012 ESMO Guidelines: Sequence of Treatment by Line
Schmoll et al. Ann Oncol. 2012;23:2479-2516.
![Page 15: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/15.jpg)
15
EGFR: One of Many Signaling Modules in Cancer Cells
Hanahan, Weinberg, Cell 100:57, 2000
![Page 16: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/16.jpg)
16Proliferation MetastasisAngiogenesisApoptosis
Resistance
Shc
PI3-K
RafMEKK-1
MEKMKK-7
JNKERK
Ras
mTOR
Grb2
AKT
Sos-1
What is the Role of the Epidermal Growth Factor Receptor (EGFR) in Cancer?
Cell Membrane
EGFR
Signaling Proteins
Cell Response
to Signaling
![Page 17: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/17.jpg)
17A. Friedman and N. Perrimon, Cell 128, January 26, 2007
Pathway vs. Network signaling
Network
“Chaotic”
Pathway
“Newtonian”
![Page 18: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/18.jpg)
The Nature of the Disease
![Page 19: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/19.jpg)
19
Shc
PI3-K
RafMEKK-1
MEKMKK-7
JNKERK
Ras
mTOR
Grb2
AKT
Sos-1
Proliferation MetastasisAngiogenesisApoptosis Resistance
EGFR
Signaling Proteins
Cell Response
to Signaling
![Page 20: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/20.jpg)
20
Shc
PI3-K
RafMEKK-1
MEKMKK-7
JNKERK
Ras
mTOR
Grb2
AKT
Sos-1
Which Target?
![Page 21: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/21.jpg)
21
Courtesy of I. Serebriiskii and E. Golemis, Fox Chase Cancer Center
Sos-1
Ras
MEKK-1MEK
Shc
PI3-K
Raf
MKK-7
Grb2
AKT
JNK
ERK
![Page 22: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/22.jpg)
22
Courtesy of I. Serebriiskii and E. Golemis, Fox Chase Cancer Center
Sos-1
Ras
MEKK-1MEK
Shc
PI3-K
Raf
MKK-7
Grb2
AKT
JNK
ERK
Where’s the target?
The EGF Receptor Interactome
638 Genes
![Page 23: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/23.jpg)
23
Colon Cancer Has Many Biologic Subsets That Differ in Response to
EGFR-Targeted Agents
BRAF
KRAS
EREG or AREG
PI3K PTEN
EGFR
PIP1
PIP3
Signaling to the nucleus
Low expression of EGFR ligands → decreased response to EGFR targeted agents
Mutant BRAF → decreased response to EGFR-targeted agents
PTEN loss of expression → decreased response to EGFR-targeted agents
Mutant KRAS → decreased response to EGFR-targeted agents
![Page 24: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/24.jpg)
24
Q: Is More Always Better?
![Page 25: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/25.jpg)
25
Correlation Between Survival and Percentage of Patients Receiving Three
Drugs in Phase 3 Trials
3 drugs: 5-FU/LV, irinotecan, oxaliplatin.Grothey A, et al. J Clin Oncol. 2005;23:9441-9442.
12
13
14
15
16
17
18
19
20
21
22
0 10 20 30 40 50 60 70 80
Patients with three drugs (%)
Me
dia
n O
S (
mo
nth
s)
![Page 26: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/26.jpg)
TRIBE Study Design
R
508 mCRC pts1st lineunresectablestratified by center PS 0/1-2
adjuvant CT
FOLFIRI+bev(up to 12 cycles)
FOLFOXIRI+bev
(up to 12 cycles)
5-FU/LV +Bev
5-FU/LV +Bev
PD
INDUCTION MAINTENANCE
![Page 27: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/27.jpg)
Toxicity Profile – Safety population
G3/4 adverse events, % patients
FOLFIRI + bevN=254
FOLFOXIRI + bevN=250
p
Nausea 3 3 1.000
Vomiting 3 4 0.492
Diarrhea 11 19 0.012
Stomatitis 4 9 0.048
Neutropenia 20 50 <0.001
Febrile neutropenia 6 9 0.315
Neurotoxicity 0 5 <0.001
Hypertension 2 5 0.157
Venous Thrombosis 6 7 0.593
Arterial Thrombosis 2 1 1.000
Bleeding 1 1 1.000
![Page 28: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/28.jpg)
Secondary endpoint: Response rate (updated) - ITT population
Best Response, %
FOLFIRI + bevN = 256
FOLFOXIRI + bevN = 252
p
Complete Response 3% 5%
Partial Response 50% 60%
Response Rate 53% 65% 0.006
Stable Disease 32% 25%
Progressive Disease 11% 6%
Not Assessed 4% 4%
![Page 29: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/29.jpg)
Median follow up: 32.3 mos
FOLFIRI + bev: N = 256 / Progressed = 226FOLFOXIRI + bev: N = 252 / Progressed = 213
FOLFIRI + bev, median PFS : 9.7 mosFOLFOXIRI + bev, median PFS : 12.1 mos
Unstratified HR: 0.77 [0.64-0.93]p=0.006
Stratified HR: 0.75 [0.62-0.90] p=0.003
Primary endpoint: PFS (updated) – ITT population
FOLFIRI/bev 256 203 94 46 26 14 7 3 0 0
FOLFOXIRI/bev 252 208 125 74 35 21 11 5 2 1
Pro
gre
ssio
n-f
ree
surv
ival
pro
bab
ility
F-up time (months)
FOLFIRI + bev
FOLFOXIRI + bev
![Page 30: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/30.jpg)
Secondary endpoint: OS (preliminary) – ITT population
FOLFIRI/bev 256 233 216 172 109 69 36 15 5 0
FOLFOXIRI/bev 252 234 205 175 119 70 35 15 4 0
Ove
rall
su
rviv
al p
rob
abili
ty
F-up time (months)
FOLFIRI + bev
FOLFOXIRI + bev
Median follow up: 32.3 mos
FOLFIRI + bev: N = 256 / Died = 155FOLFOXIRI + bev: N = 252 / Died = 131
FOLFIRI + bev, median OS : 25.8 mosFOLFOXIRI + bev, median OS : 31.0 mos
Unstratified HR: 0.83 [0.66-1.05]p=0.125
Stratified HR: 0.79 [0.63-1.00] p=0.054
![Page 31: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/31.jpg)
Contrast of Appearance vs.Expression Phenotyping
Microarray Low Risk High Risk
Microscope Low Grade High GradeTreatment
Advice
31
![Page 32: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/32.jpg)
We need to be careful with our conclusions
![Page 33: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/33.jpg)
pmTOR-immunostaining (Ventana)
Critical: Postsurgical ischemia
![Page 34: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/34.jpg)
34
Colon Cancer is more than one disease
kRAS Wild Type kRAS mutant
MSI-High MSS
+ EGFR Agents - EGFR Agents
? No 5FU
50-60% 40-50%
15-20% 80-85%
And of course it is very many more than the 4 sub-groups above
![Page 35: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/35.jpg)
Clinical Research 2.0
![Page 36: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/36.jpg)
Agent HR $ Cost/Month(÷100)
Toxicity(G1+2) * (G3+4) # Patients
QOL/Utility ScorePass/Fail
Imatinib vs IFNCML 0.17 55.90 0.67
Nilotinib vs ImatCML 0.8 76.40 0.17
ImatinibGIST 0.4 55.90 1.22
Erlotinib vs ChemoMut NSCL
0.75 52.80 0.71
ErlotinibPancreas 0.82 52.80 11.9
Bevacizumab 2nd line CRC 0.74 22.90 0.8
Aflibercept2nd line CRC 0.79 ????- 3.0
Value Metric
![Page 37: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/37.jpg)
Finding Value
• Come together• Listen to each other• Respect what we hear• Find the common threads• Weave a new fabric
- provide global healthcare with value
![Page 38: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/38.jpg)
![Page 39: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/39.jpg)
Engaging the 97%• Better education/information• Incentives for patients and providers
– No added incentives for delivering SOC– Honor our “soldiers” in the war on cancer
• Recognized the shared investment in research– Docs, hospitals, NCI, Industry, Payers, Patients
• Target “substantial therapeutic benefit”– “Breakthrough Designation”
• Reduce concept to approval time line• Embrace the emerging markets
![Page 40: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/40.jpg)
Fundamental Shifts In Cancer CareYesterday• Consumption• Individual Practices• Rich Countries• Microscope• Safety and Efficacy• Large trials• 1.4 months• QOL• Patient as a “Subject”• Chaotic Data Collection• Institutional IRBs• National Approvals
Tomorrow• Outcomes• Healthcare Systems• All Countries• Gene Profile• Value• Small trials• “Substantial Improvement”• Patient Reported Outcomes• Patient as a “Partner”• Standard Data Collection• Central/National IRBs• Global Approvals
![Page 41: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/41.jpg)
![Page 42: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/42.jpg)
Questions & Answers
![Page 43: Colorectal Cancer: What’s New and What’s on the Horizon](https://reader038.vdocument.in/reader038/viewer/2022103000/5560e55cd8b42a3d768b4e0b/html5/thumbnails/43.jpg)
Thank you!
Fight Colorectal CancerAnswer Line 1-877-427-2111FightColorectalCancer.org
Colon Cancer AllianceHelpline: 1-877-422-2030
www.CCAlliance.org [email protected]